BridgeMD
New treatment option for Brain Cancer
Official title Precision Radiotherapy Enabled by Molecular MRI
ClinicalTrials.gov ID: NCT07512154
What this study is testing
- What it's testing
- This is a research study to determine if a novel molecular magnetic resonance imaging (MRI) technique, called amide proton transfer (APT) imaging, is useful in identifying the most aggressive areas of tumor needed for radiotherapy of brain tumors.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologic confirmation of glioblastoma or grade 4 astrocytoma
- Age \>18
- KPS at least 60
- Patients must have normal organ and marrow function as defined below:
- leukocytes \>3,000/mcL
You likely can't join if
- Patients who are unable to receive MRIs will be excluded from the study.
- Patients may not be receiving any other investigational cancer treatment agents at the time of enrollment.
- Patients may not have previously been treated with an overlapping course of radiotherapy to the brain.
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina...
- Pregnant and/or breastfeeding women are excluded. Women of child-bearing potential who are unwilling or unable to use an acceptable method of birth...
See the full eligibility criteria
- Histologic confirmation of glioblastoma or grade 4 astrocytoma
- Age \>18
- KPS at least 60
- Patients must have normal organ and marrow function as defined below:
- leukocytes \>3,000/mcL
- absolute neutrophil count \>1,500/mcL
- platelets \>100,000/mcL
- total bilirubin within normal institutional limits
- AST(SGOT)/ALT(SGPT) \<2.5
- institutional upper limit of normal
- creatinine within normal institutional limits OR creatinine clearance \>60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
- Patients of child-bearing potential (male or female) must practice adequate contraception due to possible harmful effects of radiation therapy on an unborn child.
- Ability to understand and the willingness to sign a written informed consent document.
- Patients who are unable to receive MRIs will be excluded from the study.
- Patients may not be receiving any other investigational cancer treatment agents at the time of enrollment.
- Patients may not have previously been treated with an overlapping course of radiotherapy to the brain.
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations...
- Pregnant and/or breastfeeding women are excluded. Women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 12...
The study team makes the final eligibility decision.
Where it's taking place
- Baltimore, Maryland, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Baltimore, Maryland, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.